-
The Relevance of the Use of TENS Devices in the Therapy of Poststroke Dysphagia
Sep 9, 2025, 16:22 PM -
The Role of Environmental Evidence in HTA: Comparative Insights Into Global Assessment Frameworks
Sep 9, 2025, 16:22 PM -
Association of eGFR Decline and Cardiovascular Outcomes in Chronic Kidney Disease Patients: Feasibility of Frequency Matching Replicating Event-Driven Clinical Trials With Real-World Data Long-Term
Sep 9, 2025, 16:22 PM -
EIGER: Cost Impact of Progression to Metastatic Disease Amongst US Patients With Gastric and Gastroesophageal Junction Cancer (GCGEJC)
Sep 9, 2025, 16:22 PM -
Health Technology Assessment (HTA) Systems and Risk Identification Strategies: A Comparative Analysis Across Western European Countries, Canada, and Australia
Sep 9, 2025, 16:22 PM -
AI Models for Predicting Clinical Trial Success: Capabilities and Risks of Pattern-Driven Approaches
Sep 9, 2025, 16:22 PM -
Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)
Sep 9, 2025, 16:22 PM -
Utilization of Real-World Evidence (RWE) in AMNOG Dossiers Following the 2024 GBA Revision of Module 3 Requirements
Sep 9, 2025, 16:22 PM -
Modeling Early vs. Late Intervention Strategies: The Case of Dupilumab in Children With Severe Atopic Dermatitis
Sep 9, 2025, 16:22 PM -
Evaluating the Societal and Economic Impact of Immunotherapy for Melanoma Treatment in Bulgaria
Sep 9, 2025, 16:22 PM -
Development of an Indicator-Based Framework for Epidemic Phase Classification in Emerging Respiratory Infectious Diseases
Sep 9, 2025, 16:22 PM -
Infective Endocarditis Following FRANCE-TAVI Insights
Sep 9, 2025, 16:22 PM -
Addressing Payer Concerns: Opportunities for HEOR in Orphan Drug Development
Sep 9, 2025, 16:22 PM -
Meaningful Within-Patient Change of the IWQOL-Lite-CT Physical Function Composite in Adults With Obesity
Sep 9, 2025, 16:22 PM -
Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Patient-Reported Outcomes (PROs) in Asthma Biologic Late-Phase Studies and Approved Labels: Implications for Entry and Product Differentiation
Sep 9, 2025, 16:22 PM -
Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study
Sep 9, 2025, 16:22 PM -
Cost per Responder Analysis of Teclistamab Compared to Real-World Physician’s Choice of Carfilzomib and/or Pomalidomide-Based Regimens for Triple-Class Exposed Patients With Refractory/Relapsed Multiple Myeloma
Sep 9, 2025, 16:22 PM -
Characteristics Associated With the Presence of a Functional Limitation Among Adults With Asthma in the United States: Findings From the Medical Expenditure Panel Survey Study
Sep 9, 2025, 16:22 PM -
Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies
Sep 9, 2025, 16:22 PM
